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Background: The presence of non-reversible airway obstruction (AO) in never smokers has only
received limited attention until now.
Methods: We analyzed data from the Austrian Burden of Obstructive Lung Disease (BOLD)
study. We defined non-reversible AO as post-bronchodilator FEV1/FVC <0.7 which corresponds
to COPD I and higher (COPD Iþ) according to current GOLD guidelines. Significant AO was
defined as FEV1/FVC <0.7 and FEV1 <80% predicted (GOLD II and higher, GOLD IIþ). The
prevalence and characteristics of non-reversible AO in never smokers were analyzed in relation
to the severity of the disease.
Results: Never smokers comprised 47.3% of the study population. Non-reversible AO was seen
in 18.2% of never smokers, and 5.5% of never smokers fulfilled criteria for significant non-
reversible AO (GOLD stage IIþ). Therefore, the resulting population prevalence of significant
non-reversible AO (GOLD stage IIþ) was 2.6%. Never smokers with non-reversible AO were
predominantly female and slightly older. The airway obstruction was found to be less severe
as compared with ever smokers. Despite this, 20% of never smokers with significant non-
reversible AO (GOLD stage IIþ) reported respiratory symptoms and 50% reported impairment
of quality of life. This burden of illness in never smokers was similar to that in smokers when
severity of AO was taken into account.
Conclusion: Approximately every third subject with non-reversible AO has never smoked, yet
still demonstrates a substantial burden of symptoms and impairment of quality of life. Never
smokers should receive far greater attention when efforts are undertaken to prevent and treat
chronic airway obstruction.
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1834 B. Lamprecht et al.Introduction which corresponds to FEV1/FVC <0.70 and a predicted FEV1On a global scale, the majority of chronic non-reversible
airway obstruction occurs in current or former smokers.
However there is evidence that subjects who have never
actively smoked themselves can also develop chronic
airflow limitation and might thus comprise a substantial
proportion of this disorder.1
Our understanding of genetic and environmental risk
factors for the development of chronic, non-reversible
airway obstruction is still incomplete and this is especially
true for never smokers. Although this disorder appears to be
fairly prevalent in never smokers, only a limited number of
studies have described this population in greater detail.1e3
To estimate the burden of non-reversible airway obstruc-
tion in never smokers, we analyzed data from the population-
based Austrian Burden of Obstructive Lung Disease (BOLD)
study.4 We reported the prevalence in never smokers and
described the presence of symptoms and their impact on
health-related quality of life.
Materials and Methods
Study population
The population consisted of participants of the Austrian
Burden of Obstructive Lung Disease (BOLD) study.4 In this
study, a gender-stratified random sample of the inhabitants
of Salzburg County aged 40 years and over was surveyed. The
studywas approved by the local Ethics Committee of Salzburg
County, and all participants gave written informed consent.
Study measures
Spirometry was done according to American Thoracic
Society (ATS) criteria5 by trained and certified technicians
using the NDD Easy One spirometer. Separate measure-
ments were taken before and at least 15 min after two
puffs of salbutamol (200 mcg). Only spirograms that met
ATS acceptability and reproducibility criteria5 were
included. Of the 1349 participants with post-bronchodilator
spirometry, 1258 (93%) met the quality control criteria and
were included in this analysis.
Questionnaire data
The BOLD questionnaires, administered by trained and
certified staff, included information on respiratory symp-
toms, risk factors for COPD, health status, co-morbidities,
respiratory diagnoses, and limitation of activity. The BOLD
Core questionnaire was developed from pre-existing
validated questionnaires that had already been used in
multi-national studies when possible.6
Definitions
In accordance to the GOLD guidelines, non-reversible
airway obstruction was defined as a post-bronchodilator
FEV1/FVC <0.70, which corresponds to GOLD stage I and
higher. We also reported data for GOLD stage II or higher,<80%. COPD GOLD stage II or higher was defined as
clinically significant disease. The NHANES III reference
equations were used to calculate predicted values and
lower limits of normal (LLNs).7
Doctor-diagnosed COPD was defined as a self-reported
physician’s diagnosis of chronic bronchitis, emphysema, or
COPD.
Ever smoking (current or former smoking) was defined as
smoking more than 20 packs of cigarettes in a lifetime or
more than 1 cigarette/day for a year.
Exposure to passive smoke (y/n) was defined as an
affirmative answer to the question asking whether anyone
(other than the participant) had smoked a cigarette, pipe
or cigar in the home during the past two weeks.
Exposure to agricultural dust (farming), flour, feed or
grain milling, and cotton or jute processing was defined as
occupational exposure to organic/biologic dust. Working
with asbestos, coal mining, hard-rock mining, foundry or
steel milling, and sandblasting was defined as occupational
exposure to inorganic dust. Welding, fire-fighting, and
chemical or plastic manufacturing was defined as occupa-
tional exposure to irritant gases, fumes or vapors. Biomass
exposure included exposure to indoor open fire with coal,
coke, wood, crop residue or dung.
Health status measures included four indicators of
participants who: (1) responded ‘‘excellent’’ or ‘‘very
good’’ when asked to rate their general health; (2)
responded ‘‘none of the time’’ or ‘‘a little of the time’’
when asked how much of their time they experienced
limitations in work or other activities ‘‘as a result of your
physical health,’’; (3) responded ‘‘none of the time’’ or ‘‘a
little of the time’’ when asked how much of their time they
accomplished less than they liked ‘‘as a result of any
emotional problems.’’; and (4) responded ‘‘none of the
time’’ or ‘‘a little of the time’’ when asked how much of
their time they felt downhearted or depressed ‘‘as a result
of your physical health’’.
Statistical analysis
In contrast to previously reported data,4 no additional
weighting class adjustments were made for sampling and
differential response rates for different age categories.
Statistical significance of differences was evaluated using
the chi-squared test and the non-parametric Manne
Whitney U-Test. All statistical analyses were done with SAS
8.2 (SAS Institute Inc, Cary, NC, USA).
Results
Prevalence of non-reversible airways obstruction
In never smokers, the prevalence of non-reversible airway
obstruction (GOLD stage Iþ) was 18.2%. Prevalence of COPD
GOLD stage IIþ was 5.5%. Altogether, never smokers
comprised 27.7% of clinically significant disease (GOLD
stage IIþ) (see Table 1). Similar GOLD stage II and higher
COPD prevalences were seen when we used local prediction
equations in place of the US NHANES III equations (data not
shown). When the presence of non-reversible airway
Table 1 Demographic characteristics and prevalence of post-bronchodilator (PBD) airway obstruction in never smokers and
ever smokers
N Age in years
median (range)
Sex, female PBD FEV1/FVC <0.7
(COPD GOLD Iþ)
PBD FEV1/FVC <0.7 & FEV1
<80% pred. (COPD GOLD IIþ)
Never smoker 595 (47.3%) 58 (40e98) 320 (53.8%)* 108 (18.2%)þ 33 (5.5%)f
Ever smoker 663 (52.7%) 55 (40e89) 253 (38.2%)* 196 (29.6%)þ 86 (13.0%)f
Total 1258 (100%) 57 (40e98) 573 (45.6%) 304 (24.2%) 119 (9.5%)
*p < 0.001; þp < 0.001; f pZ 0.023.
Table 2 Comparison of never smokers with and without
non-reversible airway obstruction
FEV1/FVC
<0.7
(NZ 108)
FEV1/FVC
>0.7
(NZ 487)
P-value
Characteristics
Age, mean (SD) 65.8 (1.2) 57.2 (0.5) <0.001
Sex, female 52.8% 54.0% 0.817
Education 12 years 22.2% 25.5% 0.511
Hospitalized for
breathing problems
<age of 10
2.8% 3.3% 0.786
Reported co-morbidities
Asthma 13.9% 5.1% <0.001
Heart disease 19.4% 10.3% 0.008
Hypertension 41.7% 31.0% 0.033
Diabetes 5.6% 6.0% 0.873
Stroke 5.6% 1.0% 0.002
Tuberculosis 2.8% 2.7% 0.950
Reported exposures
Passive smoking
at home
17.6% 15.0% 0.499
Indoor open fire with
biomass for cooking
11.1% 13.1% 0.567
Indoor open fire with
biomass for heating
12.0% 16.1% 0.299
Organic dust in
the workplace
36.1% 25.5% 0.025
Inorganic dust in
the workplace
3.7% 3.7% 0.997
Irritant gases/
fumes/vapors
in the workplace
9.3% 9.7% 0.900
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ratio below the lower limit of normal (LLN), the prevalence
of significant airway obstruction (FEV1/FVC <LLN and FEV1
<80% predicted) was 3.7%.
Risk factors for airway obstruction
in never smokers
Never smokers with non-reversible airway obstruction (GOLD
Stages Iþ) were significantly older (65.8 years vs 57.2 years,
p < 0.001) than never smokers with normal lung function.
Compared to smokers, never smokers with non-reversible
airway obstructionwere predominately female (e.g. 48.0% vs
38.2% for GOLD stage I, and 62.5% vs 32.9% for GOLD stage II).
In our data, only occupational exposure to organic dust was
found to be significant among the potential risk factors for
non-reversible airway obstruction (see Table 2).
Co-morbidities, reported and undiagnosed
airways diseases
Never smokers with airway obstruction reported signifi-
cantly more co-morbid disease than never smokers with
normal lung function (see Table 2).
In never smokers with significant non-reversible airway
obstruction (FEV1/FVC <0.7 and a predicted FEV1 <80%,
GOLD stage IIþ) only 21.2% reported a previous diagnosis of
either asthma (12.1%) or COPD (9.1%). Therefore, 78.8% of
never smokers with significant non-reversible airway
obstruction were previously undiagnosed.
If all subjects who reported a prior doctor’s diagnosis of
‘‘asthma’’ were excluded from the analyses, the preva-
lence of significant non-reversible airway obstruction in
never smokers would decrease from 5.5% to 4.9%.
Respiratory symptoms and health-related
quality of life
When never smokers and smokers demonstrated the same
degree of airway obstruction, theywere found to be similar in
respect to the presence of respiratory symptoms (see
Figure 1) and their health-related quality of life. Further-
more, presence of symptoms and impairment of quality of life
increased in both groups parallel to the severity of disease.
Discussion
The results of our population-based study show that never
smokers comprised 35% of all cases of non-reversible airwayobstruction and 28% of significant airway obstruction (GOLD
stage IIþ) in adults aged 40 years and over.
Risk factors for airway obstruction
in never smokers
In our data, never smokers with non-reversible airway
obstruction were predominately female. This was even
more pronounced in significant disease (GOLD stage IIþ).
This finding is consistent with the results of a population-
based study in Spain, which showed that women 55 years
and over constitute the majority of COPD cases among
never smokers.3 In developing countries, biomass fuels used
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Figure 1 Presence of reported respiratory symptoms in never smokers and ever smokers according to severity of non-reversible
airway obstruction. A: Dyspnea, B: wheezing, C: cough, and D: phlegm.
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cause COPD in non-smoking women.8e11 As some studies
have suggested that women are more susceptible to the
effects of tobacco smoke,12,13 this could probably also
apply for other exposures.
In our data, occupational exposure to organic dust was
associated with a higher prevalence of non-reversible
airway obstruction in never smokers. By definition, farming
was categorized as occupational exposure to organic/
biologic dusts. This particular exposure has previously been
shown to be a risk factor for airway obstruction in the
observed population.14 This is consistent with results of
a study in never smoking animal farmers in which an asso-
ciation between dust concentration and prevalence of
COPD was shown.15
We did not found an association between passive
smoking and non-reversible airway obstruction in never
smokers. This could be due to the fact that the question-
naire only assessed current exposure to passive smoking
(within the last 2 weeks) but included no information about
a history of exposure to passive smoking.
Definition of airway obstruction, rate of
underdiagnosis and potential misclassification
The definition of airway obstruction using the GOLD criteria
may lead to some overdiagnosis of COPD in elderly never
smokers.16 Prevalence of airway obstruction is always
a matter of definition. At present, the GOLD initiative
continues to recommend the use of a fixed ratio,post-bronchodilator FEV1/FVC <0.7, to define airflow limi-
tation,17 whereas a joint ATS/ERS Task Force has proposed
using the Lower Limit of Normal (LLN) as a cut-off value for
the FEV1/FVC ratio.
18 In our data, the prevalence of
significant non-reversible airway obstruction in never
smokers decreased by 33% when the LLN was used instead
of the fixed ratio.
The present authors have decided to present the data on
non-reversible airway obstruction in never smokers using
the fixed ratio of post-bronchodilator FEV1/FVC <0.7,
because currently recommended prediction equations for
LLNs are based on pre-bronchodilator spirometry data.7
Finally, a main problem with chronic airways disease might
not be the most precise definition of airway obstruction but
the fact that many affected people are undiagnosed and
untreated.19 In our data, the prevalence of doctor diag-
nosed COPD was far below the true burden in both smokers
and never smokers. The proportion of previously undiag-
nosed obstructive airways disease was 78.8% in never
smokers and 74% in smokers.
In our data, 14% of never smokers with non-reversible
airway obstruction and 12% of never smokers with signifi-
cant non-reversible airway obstruction reported a prior
physician’s diagnosis of asthma. As we determined post-
bronchodilator airway obstruction, it seems reasonable
that the majority of them suffer from COPD not asthma.
However, when we excluded all subjects who reported
a prior doctor’s diagnosis of ‘‘asthma’’, the prevalence
of significant non-reversible airway obstruction only
decreased from 5.5% to 4.9%.
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quality of life and co-morbidities
The comparison of never smokers and smokers with non-
reversible airway obstruction did not show a difference in
terms of respiratory symptoms or health-related quality of
life when the comparison was stratified by the severity of
airway obstruction. Given this similar impact of airway
obstruction on the subjective burden of disease, one could
argue that a comparable lifetime burden of inhalational
injury will lead to chronic inflammation and subsequent
chronic airway disease irrespective of its origin.
Never smokers with non-reversible airway obstruction
reported significantly higher amounts of co-morbidities
(ischemic heart disease, hypertension) than never smokers
with normal lung function. This again supports the argu-
ment that chronic airway obstruction in never smokers and
ever smokers follows a similar course and involves
co-morbid cardiovascular disease in either instance.
Limitations and conclusions
The site-specific sampling plan adopted for BOLD was not
designed to provide sufficient power to clarify potential risk
factors in detail. In particular, the assessment of passive
smoking and occupational exposure by questionnaire was
not sufficient to demonstrate a relationship with non-
reversible airway obstruction in never smokers. The
number of study participants in some occupations known to
be risk factors for airways disease was far too low for
a more detailed analysis.
However, never smokers who fulfill the criteria of COPD
seem to have the same respiratory symptoms and breathing
problems interfering with their daily life as smokers. The
current GOLD guidelines recommend spirometry testing,
when either risk factors or respiratory symptoms are
present.17 This might be a disadvantage for never smokers
who don’t have spirometry testing before the disease has
become more severe and respiratory symptoms have
developed. Due to the fact that more than 5% of adult
never smokers suffer from significant non-reversible airway
obstruction, spirometry testing should not be limited to
smokers.
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